Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
The quarterly results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early November.
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
The quarterly results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early November.
BP shares rise 5% after British oil giant announces plans to boost shareholder returns
British oil giant BP on Tuesday announced plans to boost shareholder returns, even after a sharp drop in full-year profits aligned with lower oil prices.
BP shares rise 5% after British oil giant announces plans to boost shareholder returns
British oil giant BP on Tuesday announced plans to boost shareholder returns, even after a sharp drop in full-year profits aligned with lower oil prices.
BP shares rise 6% after British oil giant announces plans to boost shareholder returns
British oil giant BP on Tuesday announced plans to boost shareholder returns, even after a sharp drop in full-year profits aligned with lower oil prices.
BP shares rise 6% after British oil giant announces plans to boost shareholder returns
British oil giant BP on Tuesday announced plans to boost shareholder returns, even after a sharp drop in full-year profits aligned with lower oil prices.
Oil major BP accelerates pace of share buybacks after sharp drop in full-year profit
British oil giant BP on Tuesday reported weaker-than-expected annual profits, following declines in fossil fuel prices.
Palantir stock jumps 19% as AI demand drives revenue beat
Palantir reported fourth-quarter earnings after the bell Monday.
Palantir stock jumps 19% as AI demand drives revenue beat
Palantir reported fourth-quarter earnings after the bell Monday.
Palantir stock jumps 19% as AI demand drives revenue beat
Palantir reported fourth-quarter earnings after the bell Monday.